Skip to main content
WGS logo

GeneDx Holdings Corp. (WGS) Stock: Price, Forecast & Analyst Target

GeneDx Holdings Corp. (WGS) — MoonshotScore 18/100 (Weak band), calculated Nov 18, 2026. Price $51.96 (+9.88%), as of the Nov 18, 2026 trading session; market cap $1.56B.

Educational signal · not a buy or sell recommendation · How to read this

$51.96 +$4.67 (+9.88%) Market Cap $1.56B

GeneDx Holdings Corp. · WGS · NASDAQ

GeneDx Holdings Corp. is a patient-centered health intelligence company transforming healthcare through AI and machine learning applied to clinical and genomic data. Their Centrellis platform aims to provide science-driven solutions for pressing medical needs by creating dynamic models of human health.

Price as of Nov 18, 2026

Key Statistics

18 of 100

MoonshotScore v2 · GeneDx Holdings (WGS)

Weak
Business Quality Solid (61)
Financial Safety Fragile (11)
Valuation Full (52)
Growth Durability Shrinking (17)
Momentum Slipping (37)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fragile balance sheet, stalling growth and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Shrinking; Momentum: Slipping.

  • EPS beat 1 of the last 3 reports
  • Altman Z -0.16 · Piotroski F 3
  • ROE -41.4% · ROA -7.7% · current ratio 4.16

Holding back: balance-sheet strain, soft growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for WGS (57 recorded, newest six shown)
RecordedScoreBand
25Weak
28Weak
23Weak
23Weak
18Weak
18Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$51.96
Change on the day+9.88%
52-week range$32.21 – $170.87
Market capitalisation$1.56B—
Price / earnings (trailing)41.40
Shares traded on the day1.71M

Price & events

Other perspectives

Council score for GeneDx Holdings (WGS): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Neutral
Growth Durability Negative
Momentum Weak

Legends Council

3 lenses, 3 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Weak
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is GeneDx Holdings (WGS), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. GeneDx Holdings Corp. (WGS) is listed on NASDAQ. It employs 1,300 people and is led by Katherine A. Stueland. The market values it at $1.56B.

2 · Latest results

What do the latest results show for GeneDx Holdings (WGS)?

Short answer · as of

Against analyst estimates the company has EPS beat 1 of the last 3 reports.

Quarterly income statement — 3 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$117M-$8M-$0.27 (diluted)
Q4 FY2025$121M-$18M—
Q1 FY2026$102M-$63M-$2.16 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for GeneDx Holdings (WGS)?

Short answer

What is holding it back is balance-sheet strain, soft growth. The distress and quality screens read Altman Z -0.16 · Piotroski F 3. Trailing ratios: ROE -41.4% · ROA -7.7% · current ratio 4.16.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -0.16 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-41.4%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at GeneDx Holdings (WGS)?

Short answer · as of

Current published price targets run low $63.00 · high $90.00 · consensus $80.25 · median $84.00 against a quoted price of $51.96 (as of Nov 18, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does GeneDx Holdings compare with its peers?

Short answer

GeneDx Holdings's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Oscar Health, Inc. (OSCR) Named competitor$27.57 Nov 18, 2026$8.57B97 5-pillar Nov 18, 2026
BillionToOne, Inc. (BLLN) Same industry, near in market value$91.54 Nov 18, 2026$4.37B94 5-pillar Nov 18, 2026
CareDx, Inc (CDNA) Same industry, near in market value$74.44 Nov 18, 2026$3.91B84 5-pillar Nov 18, 2026
Privia Health Group, Inc. (PRVA) Named competitor$24.60 Nov 18, 2026$3.14B79 5-pillar Nov 18, 2026
Fulgent Genetics, Inc. (FLGT) Same industry, near in market value$25.13 Nov 18, 2026$702M39 5-pillar Nov 18, 2026
Castle Biosciences, Inc. (CSTL) Same industry, near in market value$33.38 Nov 18, 2026$1.03B37 5-pillar Nov 18, 2026
NeoGenomics, Inc. (NEO) Same industry, near in market value$15.29 Nov 18, 2026$1.98B35 5-pillar Nov 18, 2026
Neogen Corporation (NEOG) Same industry, near in market value$11.08 Nov 18, 2026$2.42B34 5-pillar Nov 18, 2026
Immunovant, Inc. (IMVT) Named competitor$33.17 Nov 18, 2026$6.86B25 5-pillar Nov 18, 2026
NewAmsterdam Pharma Company N.V. (NAMS) Named competitor$19.74 Nov 18, 2026$2.37B24 5-pillar Nov 18, 2026
Personalis, Inc. (PSNL) Same industry, near in market value$14.98 Nov 18, 2026$1.62B24 5-pillar Nov 18, 2026
OPKO Health, Inc. (OPK) Same industry, near in market value$1.69 Nov 18, 2026$1.25B19 5-pillar Nov 18, 2026
GeneDx Holdings (WGS) — this page$51.96$1.56B18

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$63.00 – $90.00
Consensus target
$80.25
Median target
$84.00

Consensus record · Captured .

Measured against a quoted price of $51.96 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 17, 2026

Transactions
62
Identified insiders
11
Purchases
2
Sales
21
Other transactions
39

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held WGS in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20260.80%$138.32MAdded +18.8% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about GeneDx Holdings (WGS)?

Read these with our analysis →

GeneDx Holdings Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the WGS research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for WGS?

WGS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is WGS a good stock to buy?

Stock Expert AI does not rate WGS buy, sell or hold. GeneDx Holdings Corp. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the WGS stock price today?

The last price recorded for GeneDx Holdings Corp. (WGS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the WGS price target?

The analyst consensus price target for GeneDx Holdings Corp. (WGS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What do analysts say about WGS stock?

Analyst consensus on GeneDx Holdings Corp. (WGS) reflects a mixed outlook, acknowledging the company's innovative approach to healthcare through AI and machine learning.

What are the key factors to evaluate for WGS?

GeneDx Holdings Corp. (WGS) holds a MoonshotScore in the low range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. No dividend yield, suggesting that the company is reinvesting earnings for growth. Not financial advice.

How frequently does WGS data refresh on this page?

WGS's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven WGS's recent stock price performance?

GeneDx Holdings Corp. (WGS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Centrellis platform leveraging AI and machine learning. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider WGS overvalued or undervalued right now?

The trailing P/E of GeneDx Holdings Corp. (WGS) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 11 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.